Pure Bioscience, Inc. (PURE) stock
PUREOTCMiscellaneous Chemical ProductsFiscal year ends July 31
$0.07−0.01 (-12.10%)
Close on Oct 19, 2026Market cap $8.67MP/E –Yield –
Pure Bioscience operating margin
Operating margin is operating income as a percentage of revenue.
Pure Bioscience's operating margin for the twelve months ending Jul 31, 2026 was -90.0%. For fiscal 2026 it was -90.0%, against -103.4% the year before. The highest annual figure on record is 0.1% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2026 | Jul 31, 2026 | -90.0% | +13.4 |
| FY2025 | Jul 31, 2025 | -103.4% | +59.9 |
| FY2024 | Jul 31, 2024 | -163.2% | +47.5 |
| FY2023 | Jul 31, 2023 | -210.7% | −5.3 |
| FY2022 | Jul 31, 2022 | -205.4% | −142.9 |
| FY2021 | Jul 31, 2021 | -62.5% | −62.6 |
| FY2020 | Jul 31, 2020 | 0.1% | +292.8 |
| FY2019 | Jul 31, 2019 | -292.8% | +104.2 |
| FY2018 | Jul 31, 2018 | -397.0% | −68.8 |
| FY2017 | Jul 31, 2017 | -328.1% | +219.4 |
| FY2016 | Jul 31, 2016 | -547.5% | +500.5 |
| FY2015 | Jul 31, 2015 | -1048.0% | +1116.0 |
| FY2014 | Jul 31, 2014 | -2164.0% | −1269.0 |
| FY2013 | Jul 31, 2013 | -895.0% | +183.1 |
| FY2012 | Jul 31, 2012 | -1078.1% | +725.2 |
| FY2011 | Jul 31, 2011 | -1803.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2026CQ2 2026 | Jul 31, 2026 | -76.3% | −32.3 |
| Q3 FY2026CQ1 2026 | Apr 30, 2026 | -102.4% | +17.1 |
| Q2 FY2026CQ4 2025 | Jan 31, 2026 | -154.2% | +31.2 |
| Q1 FY2026CQ3 2025 | Oct 31, 2025 | -53.6% | +59.4 |
| Q4 FY2025CQ2 2025 | Jul 31, 2025 | -44.0% | +104.1 |
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | -119.4% | +66.3 |
| Q2 FY2025CQ4 2024 | Jan 31, 2025 | -185.4% | +111.2 |
| Q1 FY2025CQ3 2024 | Oct 31, 2024 | -113.0% | −13.9 |
| Q4 FY2024CQ2 2024 | Jul 31, 2024 | -148.1% | +22.0 |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | -185.7% | +29.8 |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | -296.6% | −29.4 |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | -99.0% | +112.1 |
| Q4 FY2023CQ2 2023 | Jul 31, 2023 | -170.1% | +134.4 |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | -215.5% | −62.8 |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | -267.2% | −40.7 |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | -211.1% | −51.2 |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | -304.5% | −219.5 |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | -152.7% | −7.0 |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | -226.5% | −158.1 |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | -160.0% | −147.3 |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | -84.9% | −118.4 |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | -145.7% | −167.0 |
| Q2 FY2021CQ4 2020 | Jan 31, 2021 | -68.4% | +121.5 |
| Q1 FY2021CQ3 2020 | Oct 31, 2020 | -12.6% | +271.3 |
| Q4 FY2020CQ2 2020 | Jul 31, 2020 | 33.5% | +167.6 |
| Q3 FY2020CQ1 2020 | Apr 30, 2020 | 21.3% | +313.6 |
| Q2 FY2020CQ4 2019 | Jan 31, 2020 | -190.0% | +137.9 |
| Q1 FY2020CQ3 2019 | Oct 31, 2019 | -283.9% | +150.5 |
| Q4 FY2019CQ2 2019 | Jul 31, 2019 | -134.1% | +136.2 |
| Q3 FY2019CQ1 2019 | Apr 30, 2019 | -292.3% | +146.4 |
| Q2 FY2019CQ4 2018 | Jan 31, 2019 | -327.9% | +165.5 |
| Q1 FY2019CQ3 2018 | Oct 31, 2018 | -434.4% | −19.1 |
| Q4 FY2018CQ2 2018 | Jul 31, 2018 | -270.3% | +4.2 |
| Q3 FY2018CQ1 2018 | Apr 30, 2018 | -438.7% | +32.6 |
| Q2 FY2018CQ4 2017 | Jan 31, 2018 | -493.4% | −179.3 |
| Q1 FY2018CQ3 2017 | Oct 31, 2017 | -415.3% | −114.5 |
| Q4 FY2017CQ2 2017 | Jul 31, 2017 | -274.6% | – |
| Q3 FY2017CQ1 2017 | Apr 30, 2017 | -471.3% | – |
| Q2 FY2017CQ4 2016 | Jan 31, 2017 | -314.1% | – |
| Q1 FY2017CQ3 2016 | Oct 31, 2016 | -300.8% | – |
See a number that looks wrong?